Carcinoma de células escamosas vaginales y vulvares · línea 1 · Pembrolizumab en monoterapia
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
| Línea de tratamiento | 1 |
|---|---|
| Track | estándar |
| Régimen vinculado | REG-PEMBROLIZUMAB-MONO |
| ID | IND-VULVAR-VAGINAL-SCC-METASTATIC-1L-PEMBRO |
|---|---|
| Tipo | Indicación |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | DIS-VULVAR-VAGINAL-SCC |
| Fuentes | SRC-KEYNOTE-158-VULVAR-SHAPIRA-FROMMER-2022 |
Notas
STUB pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted per CHARTER §8.3 — draft content only, NOT published/verified clinical advice). KEYNOTE-158 vulvar cohort enrolled PREVIOUSLY TREATED advanced disease (typically post-platinum or post-chemoradiation), not treatment-naive metastatic disease — this Indication is nonetheless positioned as the metastatic '1L systemic' option in ALGO-VULVAR-VAGINAL-SCC-1L per this authoring pass's scope, because no platinum-based cytotoxic chemotherapy Indication is yet authored for metastatic vulvar/vaginal SCC (open gap). PD-L1 CPS gating is a cross-tumor convention applied here for consistency with other pembrolizumab Indications in this KB, NOT a vulvar-SCC-validated cutoff — KEYNOTE-158 vulvar cohort responses occurred regardless of PD-L1 status (see RF-VULVAR-VAGINAL-SCC-PDL1-CPS-1-PLUS notes). Reuses REG-PEMBROLIZUMAB-MONO and DRUG-PEMBROLIZUMAB entirely unchanged — no existing file was modified.
Utilizado por
Algoritmos
ALGO-VULVAR-VAGINAL-SCC-1L- ALGO-VULVAR-VAGINAL-SCC-1L
Enfermedad
DIS-VULVAR-VAGINAL-SCC- Carcinoma de células escamosas vaginales y vulvares